Why Biotech Needs Partners—and an Informed Public

On the day he spoke with TechNode, Shuyuan Ling published a WeChat blog on targeted cancer therapy—why it centers on molecular targets, the treatments those targets have enabled, and why it is no cure-all. Patients must understand unfamiliar terms before they can embrace innovations such as immunotherapy, CAR-T, and proton and heavy-ion therapy, Ling said. “If people think ‘target’ is just something doctors made up to fool them, how can they choose these innovations?” A preview card for Ling’s W